May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration
Author Affiliations & Notes
  • A. M. Minnella
    Ophthalmology, Catholic University, Rome, Italy
  • B. Falsini
    Ophthalmology, Catholic University, Rome, Italy
  • A. Scupola
    Ophthalmology, Catholic University, Rome, Italy
  • P. Sasso
    Ophthalmology, Catholic University, Rome, Italy
  • L. Ziccardi
    Ophthalmology, Catholic University, Rome, Italy
  • G. Stifano
    Ophthalmology, Catholic University, Rome, Italy
  • L. Montrone
    Ophthalmology, Catholic University, Rome, Italy
  • D. Marangoni
    Ophthalmology, Catholic University, Rome, Italy
  • A. Mastrocola
    Ophthalmology, Catholic University, Rome, Italy
  • E. Balestrazzi
    Ophthalmology, Catholic University, Rome, Italy
  • Footnotes
    Commercial Relationships  A.M. Minnella, None; B. Falsini, None; A. Scupola, None; P. Sasso, None; L. Ziccardi, None; G. Stifano, None; L. Montrone, None; D. Marangoni, None; A. Mastrocola, None; E. Balestrazzi, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2716. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. M. Minnella, B. Falsini, A. Scupola, P. Sasso, L. Ziccardi, G. Stifano, L. Montrone, D. Marangoni, A. Mastrocola, E. Balestrazzi; Short-Term Functional Results After Intravitreal Bevacizumab (AvastinTM) for Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2716.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess the short-term effects of intravitreal bevacizumab injection on retinal function by focal electoretinogram (fERG) and microperimetry (MP1).

Methods: : Twenty-one patients with exudative age related-macular degeneration (AMD) were treated with 0.125 mg/ml of intravitreal bevacizumab and evaluated, before and after injection, by best spectacle corrected visual acuity (BSCVA), fERGs to 8 Hz and 41 Hz flicker stimulation (central 18 degrees), MP1 sensitivity (central 10 degrees) and fixation stability. During 1-month follow-up, none of the patients underwent re-injection and the following parameters were considered: BSCVA, fERG 8 Hz 1st and 2nd harmonic response amplitude and 41 Hz 1st harmonic, MP1 sensitivity and 2° and 4° fixation stabillity.

Results: : When compared to baseline values, BSCVA, MP1 sensitivity and fixation stability improved (p < 0.001) at the end of study. No significant changes were observed for any of the FERG parameters. Significant positive correlations (r = 0.56; p < 0.01) were observed between microperimetry parameters and BSCVA at 30 days after injection.

Conclusions: : Results suggest an improvement of central retinal function following intravitreal bevacizumab for AMD.

Keywords: age-related macular degeneration • drug toxicity/drug effects • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×